Form D · Biotechnology
CAVU Biotherapies, Inc.
Houston, TX · CIK 0001696916
Offering snapshot reported Mar 4, 2019 · SEC filing
- Reported sold
- $50K Offering amount: $1.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 12, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 4, 2019 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Mar 17, 2017 | Initial | $75,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-334003
Convertible promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon conversion
Source: Form D, filed Mar 4, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Colleen O'connor | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
8285 El Rio Suite 110
Houston, TX, 77054
Houston, TX, 77054